Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Sees Significant Growth in Short Interest

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totalling 4,450,000 shares, an increase of 22.9% from the July 15th total of 3,620,000 shares. Based on an average trading volume of 315,700 shares, the short-interest ratio is currently 14.1 days.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on RVPH shares. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Reviva Pharmaceuticals in a research note on Thursday, July 11th. Maxim Group restated a “hold” rating on shares of Reviva Pharmaceuticals in a report on Friday. Finally, Benchmark restated a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, May 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $14.33.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Vontobel Holding Ltd. purchased a new position in shares of Reviva Pharmaceuticals in the 4th quarter valued at about $72,000. Armistice Capital LLC increased its holdings in shares of Reviva Pharmaceuticals by 194.0% in the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock valued at $9,085,000 after acquiring an additional 1,164,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Reviva Pharmaceuticals by 2.8% in the 1st quarter. Vanguard Group Inc. now owns 1,001,836 shares of the company’s stock valued at $3,787,000 after acquiring an additional 26,854 shares during the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Down 6.0 %

NASDAQ RVPH traded down $0.04 during trading hours on Friday, hitting $0.64. 549,762 shares of the company were exchanged, compared to its average volume of 304,029. The company has a 50 day moving average of $1.14 and a two-hundred day moving average of $2.42. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $6.80. The firm has a market cap of $17.98 million, a price-to-earnings ratio of -0.41 and a beta of -0.09.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. On average, equities research analysts predict that Reviva Pharmaceuticals will post -0.98 EPS for the current year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.